Santen Pharmaceutical Co., Ltd.
4536.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥494,322 | ¥520,984 | ¥437,785 | ¥490,524 |
| - Cash | ¥92,997 | ¥94,582 | ¥57,903 | ¥83,014 |
| + Debt | ¥34,229 | ¥35,158 | ¥36,207 | ¥32,932 |
| Enterprise Value | ¥435,554 | ¥461,560 | ¥416,089 | ¥440,442 |
| Revenue | ¥300,004 | ¥301,965 | ¥279,037 | ¥266,257 |
| % Growth | -0.6% | 8.2% | 4.8% | – |
| Gross Profit | ¥171,027 | ¥178,709 | ¥166,087 | ¥156,586 |
| % Margin | 57% | 59.2% | 59.5% | 58.8% |
| EBITDA | ¥68,830 | ¥56,457 | ¥14,298 | ¥54,524 |
| % Margin | 22.9% | 18.7% | 5.1% | 20.5% |
| Net Income | ¥36,247 | ¥26,642 | -¥14,948 | ¥27,218 |
| % Margin | 12.1% | 8.8% | -5.4% | 10.2% |
| EPS Diluted | 103.68 | 72.37 | -38.6 | 67.97 |
| % Growth | 43.3% | 287.5% | -156.8% | – |
| Operating Cash Flow | ¥60,928 | ¥72,649 | ¥37,147 | ¥46,043 |
| Capital Expenditures | -¥6,662 | -¥10,687 | -¥24,588 | -¥35,841 |
| Free Cash Flow | ¥54,266 | ¥61,962 | ¥12,559 | ¥10,202 |